Abstract:Abstract Background Limited by difficulties in early detection and availabilities of effective treatments, pancreatic cancer is a highly malignant disease with poor prognosis. Nuclear receptors are a family of ligand‐dependent transcription factors that are highly druggable therapeutic targets playing critical roles in human physiological and pathological development, including cancer. In this study, we explored the therapeutic potential as well as the molecular mechanisms of liver X receptor (LXR) agonist GW3965 in pancreatic cancer. Methods Soft‐agar colony formation assay, xenograft tumors, Oligonucleotide microarray, Reverse transcription real‐time polymerase chain reaction, Western immunoblotting and Immunohistochemistry were used in this study. Results We demonstrated pleotropic in vitro activities of GW3965 in pancreatic cell lines MIA PaCa‐2 and BXPC3 including reduction of cell viability, inhibition of cell proliferation, stimulation of cell death, and suppression of colony formation, which translated to significant inhibition of xenograft tumor growth in vitro. By mapping the gene expression profiles, we identified the up‐regulations of 188 and the down‐regulations of 92 genes common to both cell lines following GW3965 treatment. Genes responsive to GW3965 represent a variety of biological pathways vital for multiple cellular functions. Specifically, we identified that the activating transcription factor 4/thioredoxin‐interacting protein/regulated in development and DNA damage responses 1/mechanistic target of rapamycin (ATF4/TXNIP/REDD1/mTOR) signaling critically controls GW3965‐mediated regulation of cell proliferation/death. The significance of the ATF4/TXNIP/REDD1/mTOR pathway was further supported by associated expressions in xenograft tumors as well as human pancreatic cancer samples. Conclusions This study provides the pre‐clinical evidence that LXR agonist is a promising therapy for pancreatic cancer.

Inhibiting TrxR Suppresses Liver Cancer by Inducing Apoptosis and Eliciting Potent Antitumor Immunity

TRAF2 Inhibits Senescence in Hepatocellular Carcinoma Cells Via Regulating the ROMO1/ NAD+/SIRT3/SOD2 Axis.

The Natural Diterpenoid Isoforretin A Inhibits Thioredoxin-1 and Triggers Potent ROS-Mediated Antitumor Effects.

Inhibition of TrxR2 suppressed NSCLC cell proliferation, metabolism and induced cell apoptosis through decreasing antioxidant activity.

Inducing Ubiquitination and Degradation of TrxR1 Protein by LW-216 Promotes Apoptosis in Non-Small Cell Lung Cancer Via Triggering ROS Production

The research about the relationship between Trx system and tumor cell apoptosis as well as immune microenvironment

Inhibitory Effects of Thioredoxin Reductase Antisense RNA on the Growth of Human Hepatocellular Carcinoma Cells

Selective killing of gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation.

TR4 Nuclear Receptor Suppresses HCC Cell Invasion Via Downregulating the EphA2 Expression

Inhibitory effects of thioredoxin reductase antisense RNA on the growth of human hepatocellular carcinoma cells.

TR4 Nuclear Receptor Enhances the Cisplatin Chemo-Sensitivity Via Altering the ATF3 Expression to Better Suppress HCC Cell Growth

Cyclophosphamide As a Potent Inhibitor of Tumor Thioredoxin Reductase in Vivo.

Anti-tumor and Anti-Metastatic Effects of RRx-001 on Hepatocellular Carcinoma: Mechanisms of Action and Therapeutic Potential

Targeting the Thioredoxin System for Cancer Therapy.

Preventive Inhibition of Liver Tumorigenesis by Systemic Activation of Innate Immune Functions.

ATF4/TXNIP/REDD1/mTOR Signaling Mediates the Antitumor Activities of Liver X Receptor in Pancreatic Cancers

Potent Inhibition of Gastric Cancer Cells by a Natural Compound Via Inhibiting TrxR1 Activity and Activating ROS-mediated P38 MAPK Pathway

CCR8 antagonist suppresses liver cancer progression via turning tumor-infiltrating Tregs into less immunosuppressive phenotype

Resveratrol Exerts Antitumor Effects by Downregulating CD8+CD122+ Tregs in Murine Hepatocellular Carcinoma

Redox Status of Thioredoxin-1 (TRX1) Determines the Sensitivity of Human Liver Carcinoma Cells (hepg2) to Arsenic Trioxide-Induced Cell Death

TOX Acts as a Tumor Suppressor by Inhibiting mTOR Signaling in Colorectal Cancer